Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 116 for “"PPARG"”.
-
Understanding PPARg-Ligand Interactions to Treat Type 2 Diabetes
The incidence of type 2 diabetes mellitus (T2DM) is increasing, caused by our growingly obese population among other predisposing factors. In fact, the World Health Organisation has predicted that diabetes will be the 7th leading cause of death by 2030. Despite this, there is a shortage of …
-
The role of PPARg-dependent microRNA expression during breast tumour metastasis
Previous studies by Dr. Nicol showed the first direct in vivo evidence that peroxisome proliferator-activated receptor (PPAR)γ normally suppresses environmental chemical 7,12-dimethylbenz[a]anthracene (DMBA)-mediated breast tumour progression. Our lab also used mice with targeted knockout (KO) of …
-
Diet-induced obesity influences oocyte developmental competence via peroxisome proliferator-activated receptor gamma (PPARG)-mediated mechanisms.
… Proliferator-Activated Receptor Gamma (PPARG) agonist rosiglitazone, 10mg/kg/day. AICAR or sodium salicylate treatment did not have significant effects on the reproductive parameters examined. However, embryonic development to the blastocyst stage was significantly improved when …
-
A Novel Method for Classification and Characterization of Urothelium Cell Culture Exposed to the Different PPARg Agonists
… and characterize urothelium cell cultures under PPARg activator/inhibitor. In this project, the raw data are obtained from videos of three different cell cultures: TZ (PPARg activator), T0070907 (PPARg inhibitor) and a control culture. A cell tracking program based on the OpenCV computer vision …
-
A functional role of DOT1L in luminal muscle invasive bladder cancer
… by high expression of GATA3, FOXA1, and PPARG. PPARG is required for the normal differentiation of the urothelium and is one of the vital drivers of luminal MIBC. High PPARG expression is a key feature of luminal MIBC, however, the mechanisms of PPARG regulation are unclear and need …
-
Metabolic Regulation by Fibroblast Growth Factor 21
… was associated with increased SUMOylation of PPARg protein in this tissue. Using a feeding-fasting paradigm, I found that FGF21 expression in the liver and adipose tissue was rhythmic, peaking in liver prior to feeding and peaking in the adipose after feeding. Furthermore, the induction of …
-
Molecular Mechanisms Underlying SSRI-induced Non-alcoholic Fatty Liver Disease
… production of prostaglandin 15-deoxy-Δ12,14PGJ2 (PPARG agonist), and elevated PPARG targets involved in fatty acid uptake. Fluoxetine-induced lipid accumulation, 15-deoxy-Δ12,14PGJ2 production, and the expression of PPARG lipogenic genes were attenuated with a PTGS1 specific inhibitor. Taken …
-
Diagnóstico genético e caracterização genótipo/fenótipo de variantes do gene PPARG, precursor da lipodistrofia familiar parcial do tipo 3 em pacientes do nordeste brasileiro
… described as molecularly associated with the PPARG gene, with predominantly missense variants on chromosome 3. The syndrome causes loss of adipose tissue in the upper and lower limbs, hips, and face. It is generally associated with metabolic disorders such as type 2 diabetes, insulin …
-
Regulation of Adipocyte Transcription by PPARgamma Ligands
… Rosi functions as a high-affinity ligand for PPARgamma, the adipocyte-predominant nuclear receptor (NR). The classic model of NR action, involving binding of ligand to the NR on DNA, explains positive regulation of gene expression, but both ligand-dependent transcriptional repression and …
-
Insulin Sensitivity and the Onset of Hyperphagia in Fatty Rats
… proliferator-activated receptor gamma (PPARg), which improves insulin resistance by increasing lipogenesis in adipose tissue, we measured PPARg and fatty acid synthase (FAS) mRNA and protein at several points in development. PPARg and FAS mRNA expression was induced in fatties after the …
-
The benefits of adipocyte metabolism in bone regeneration
… peroxisome proliferator-activated receptor γ (PPARG). To that end, PPARG agonist treatment, currently known as detrimental in relation to bone, was shown to induce bone marrow adipose tissue in the distal parts of the bone such as at the fracture site and at the distal growth plate. …
-
EFFECTS OF LIPID MIXTURE AND A SELECTIVE PPARG MODULATOR ON THE DIFFERENTIATION CAPABILITIES OF HUMAN DERIVED MESENCHYMAL STEM CELLS(HADSCS) DERIVED FROM HEALTHY AN D BREAST CANCER PATIENTS
La sindrome metabolica è associata a molte complicanze che portano in particolare a malattie potenzialmente letali come l'obesità e il cancro. Per essere in grado di identificare soluzioni e trattamenti efficaci, dobbiamo indagare le cause alla base di questa sindrome. La nutrizione è un fattore …
-
Síntese de novos derivados da Tiazolidina-2,4-Diona e avaliação como potenciais agentes terapêuticos
… de docking e ligação in vitro com o receptor PPARg. Dentre os dezoito compostos, oito foram avaliados quanto a atividade in vivo pelo método do air-pouch induzido por carragenina, in sílico pelo docking no receptor PPARg e in vitro pela ligação com o domínio His-LBD-hPPARg. Estes compostos …
-
The role and regulation of PPARγ expression in muscle invasive bladder cancer
… screen aimed to identify novel regulators of PPARG gene expression that could potentially be exploited as therapeutic targets. We identified putative positive regulators of PPARG known to be involved in cellular oxidative stress response, xenobiotic detoxification, regulation of transcription, …
-
Κλινικοί και γενετικοί παράγοντες σχετιζόμενοι με την οστεονέκρωση των γνάθων σε ασθενείς με κακοήθεια που λαμβάνουν αντιοστεοκλαστικούς παράγοντες
… the presence of previously identified SNPs in PPARG and CYP2C8 genes. SNPs in both genes were associated with a higher risk of development of early BRONJ, occurring within less than 2 years of ZA therapy (59% vs. 16%, p¼.022 for PPARG and 29% vs. 7%, p¼.07 for CYP2C8) and a shorter time to …
-
Delineating Novel Genetic and MicroRNA Regulatory Mechanisms in Aggressive Subtypes of Breast Cancer
… in vivo models to assess the effects of targeted PPARg deletion in the same HER2+ transformed mammary epithelial cells that drive breast tumour progression. My data are the first to suggest PPARg loss enhances the initiation but not the progression of HER2+ breast cancer, while PPARg ligand …
Page 1 of 6